US SEC Filing Intelligence

Federal Construction & Infrastructure Contracts — August 29, 2026

The two federal construction contracts total $387.9M, both civilian, with the Department of State and Department of Transportation as the awarding agencies. The dominant theme is large-scale civilian infrastructure and institutional construction, with the highest-conviction signal being Fort Myer Construction Corp's $173M fixed-price highway reconstruction contract, which shows strong execution (93% outlaid) and low pricing risk. Caddell Construction's $214.8M State Department building contract is a material award but lacks detail on competition and pricing, presenting a neutral signal. Key risks include potential execution challenges on the fixed-price highway project and the absence of defense-related exposure, which may limit growth in a defense-heavy budget environment.

Defense Manufacturing Contracts — August 29, 2026

This digest covers a single, high-value $251.1 million firm-fixed-price contract awarded to Gulfstream Aerospace (a subsidiary of General Dynamics) by the Department of Commerce (NOAA) for G550 aircraft procurement. The contract is 100% civilian (NOAA), not defense-related, and represents a sole-source award with a 9-year performance period through 2028, of which $98.5 million has already been outlayed. The highest-conviction signal is the stable, long-term revenue stream for General Dynamics' Gulfstream segment, though the fixed-price structure and long duration introduce medium execution risk. Key watch items include NOAA's future budget allocations for aircraft modernization and any contract modifications that could alter the award's value or timeline.

VA Healthcare & Services Contracts — August 29, 2026

UnitedHealth Group's OptumRx won two identical $106.3 million firm-fixed-price delivery orders from the Department of Veterans Affairs on the same day (August 26, 2026), totaling $212.6 million in aggregate obligations for pharmacy benefit management services across two consecutive quarters (Q1 and Q2 FY25). Both contracts are civilian (0/2 defense-related), full-and-open competitive wins, signaling steady government demand for PBM services but with lumpy revenue recognition and fixed-price margin risk. The highest-conviction signal is the implied $425 million annualized run rate for VA PBM spending, though the short three-month performance periods and zero outlays to date create execution and payment uncertainty. Key risk: the firm-fixed-price structure shifts all cost risk to OptumRx, and the lack of follow-on awards beyond March 2026 leaves a revenue gap for UNH's government segment.

New Federal Contractors — August 29, 2026

Over the reporting period, seven new federal contracts totaling $2.17 billion were awarded, with only one defense-related contract, indicating a civilian-heavy procurement stream. The dominant theme is long-duration, civilian agency spending, led by MAXIMUS Federal Services' $892.8 million Department of Education debt management contract and Navarro Research's $427.6 million DOE environmental remediation award. The highest-conviction signal is MAXIMUS's competitive win, which provides a decade-plus revenue stream but carries fixed-price execution risk. Key watch items include the short-duration, high-risk OptumRx VA PBM orders and the potential for budget reallocations under a continuing resolution, which could impact civilian agency contract outlays.

Significant Contract Modifications ($10M+) — August 29, 2026

The eight contracts analyzed, totaling $2.17 billion, are overwhelmingly civilian in nature (six of eight), with only two defense-related awards. The dominant theme is stable, long-duration civilian agency spending, led by a massive $892.8 million MAXIMUS contract with the Department of Education for debt management services, which alone accounts for 41% of total obligation. The highest-conviction signal is the MAXIMUS win, a full-and-open competition that strengthens its competitive moat in government financial services. A key risk is the concentration of revenue in the MAXIMUS contract and the lumpy, short-duration $106 million OptumRx VA awards, which introduce execution and revenue visibility concerns.

8 total filings

Contract Deobligations Alert — August 29, 2026

This digest covers $2.17 billion in government obligations across 8 contracts, with only 2 defense-related awards (totaling ~$569K from DHS/ICE) and 6 civilian contracts dominating the aggregate. The highest-conviction signal is MAXIMUS FEDERAL SERVICES' $892.8 million firm-fixed-price contract with the Department of Education for debt management, representing a long-term, competitive win that underscores sustained federal investment in student loan collections. A key risk is the short-duration, high-concentration exposure for UnitedHealth Group's OptumRx, which won two $106 million VA delivery orders for a single quarter each, creating lumpy revenue and margin pressure under fixed-price terms. Investors should monitor MAXIMUS for follow-on renewals and UnitedHealth for VA Q2-Q4 PBM awards to assess recurring revenue stability.

8 total filings

Contract Option Exercises — August 29, 2026

This digest covers $2.17 billion in total obligations across 8 contract actions, with a heavy civilian tilt (6 of 8 contracts) and only 2 defense-related awards. The dominant theme is stable, long-duration civilian services: MAXIMUS INC’s $892.8 million Department of Education debt management contract and Navarro Research’s $427.6 million DOE legacy management award represent over 60% of total value. The highest-conviction signal is MAXIMUS’s competitive win in a full-and-open competition, indicating a strong moat in government financial services. Key risks include concentration in civilian agencies vulnerable to budget sequestration, and the fixed-price structure on four of the largest contracts, which introduces execution risk if costs overrun. Investors should watch the outlay pace on the Navarro contract, where only 23% has been spent, and monitor follow-on VA PBM awards for UnitedHealth Group’s OptumRx.

8 total filings

All DOE Contracts — August 29, 2026

This digest covers a single, large Department of Energy (DOE) contract awarded to Navarro Research and Engineering, Inc., valued at $427.6 million, making it a purely civilian award with no defense-related exposure. The contract, a cost-plus-award-fee arrangement for long-term surveillance, IT, and program support for the Office of Legacy Management, signals a stable, long-term revenue stream for the contractor, though only $97.1 million has been outlayed to date, leaving ~$330.5 million in potential future revenue. The highest-conviction signal is the bullish outlook for Navarro, given the contract's duration through 2021 and the low-risk cost-plus structure, but the key risk is the slow outlay rate, which suggests revenue recognition may be back-end loaded or subject to budget constraints. Investors should monitor DOE's Office of Legacy Management funding and any contract modifications or extensions as key catalysts.

Mega Contracts Monitor ($100M+) — August 29, 2026

Across seven mega-contracts worth $2.17 billion, the vast majority are civilian agency awards (6 of 7), led by a dominant $892.8 million Department of Education debt management contract to MAXIMUS INC. Defense-related awards are notably absent—only one contract touches defense-adjacent (NOAA aircraft for General Dynamics). The highest-conviction signal is MAXIMUS's decade-plus, fixed-price win, though its performance risk is material. A key risk is near-term lumpy revenue concentration at UnitedHealth Group (OptumRx), which secured $212.6 million in two three-month VA PBM delivery orders with no outlays yet. Overall, the digest points to steady civilian demand for operational services and specialized aviation, but with limited defense exposure and execution risk on fixed-price structures.

High-Value Federal Grants ($5M+) — August 29, 2026

This digest covers $2.17 billion in high-value federal obligations from a single day (August 29, 2026), with only 1 of 7 contracts defense-related, underscoring a civilian-heavy procurement stream. The dominant theme is large, long-duration service contracts at civilian agencies, led by a $892.8 million MAXIMUS FEDERAL SERVICES contract with the Department of Education for debt management, and a $427.6 million Navarro Research award from the Department of Energy for environmental remediation. The highest-conviction signal is the MAXIMUS win, which represents a decade-plus revenue stream with $544 million already outlaid, though its fixed-price structure introduces performance risk. A key risk is the $106.3 million OptumRx VA contract with zero outlays and a short three-month performance window, creating lumpy revenue and execution uncertainty for UnitedHealth Group. Overall, the digest signals stable civilian agency spending on operational services, but with limited defense exposure and notable concentration risk in two OptumRx awards to the same parent company.

DOE Energy Grants — August 29, 2026

This digest covers a single, large civilian Department of Energy (DOE) contract worth $427.6 million awarded to Navarro Research and Engineering, Inc. The contract is entirely non-defense, reflecting sustained federal commitment to environmental remediation and long-term stewardship of legacy nuclear sites. While the contract provides a substantial, low-risk revenue baseline for the small business (an estimated $63.8 million/year), the cost-plus-award-fee structure limits upside margin volatility. The highest-conviction signal is the low outlay rate (~23%), suggesting ~$330.5 million in future revenue remains unrealized. A key risk is that the contract's reported performance period ended in August 2021, meaning the current status and any extensions are unresolved and require monitoring for continuation or re-compete.

General Federal Contracts — August 29, 2026

These 7 contracts, totaling $2.17 billion across a single day in August 2026, are overwhelmingly civilian in nature (1 defense-related, but defense-related contract at just $251 million from NOAA/Gulfstream). The dominant theme is steady-state civilian agency spending, led by a massive $892.8 million Department of Education debt management win for MAXIMUS and two separate $106 million short-term VA pharmacy benefit management awards to UnitedHealth Group’s OptumRx. The highest-conviction bullish signal is MAXIMUS’s decade-long, fixed-price contract with strong past performance ($544M outlayed), though the firm-fixed-price structure carries medium execution risk. A key risk is the short three-month performance periods for OptumRx awards, creating lumpy revenue recognition and margin compression risk for UnitedHealth Group. Aggregate signal strength averages 6.3/10, indicating moderate conviction across the set.

Big Pharma Approvals — August 28, 2026

During the one-day period of August 28, 2026, two label expansion approvals were granted, with no NMEs, biosimilars, or new label expansions in the traditional sense, categorized as 'Other' due to the FALLBACK designation. The approvals span metabolic (tirzepatide) and immunology/oncology (nipocalimab) therapeutic areas, indicating continued expansion of established blockbuster franchises rather than new molecular entity innovation. The highest-conviction signal is Eli Lilly's label expansion for tirzepatide (ZEPBOUND), reinforcing its dominance in the GLP-1/GIP metabolic space, with a moderate bullish signal (5/10 strength). Key risks include potential IRA negotiation for small molecules (tirzepatide) and competitive pressure in the anti-FcRn space for nipocalimab. Overall, the period reflects incremental label expansions with moderate commercial impact, and investors should monitor payer coverage and competitive dynamics.

Orphan Drug Approvals — August 28, 2026

This digest covers three same-day label expansion approvals (August 24–25, 2026) under the Orphan Drug stream, with zero NMEs or biosimilars. The approvals are for ZANIDATAMAB-HRII (ZIIHERA) by JAZZ PHARMS, TISLELIZUMAB-JSGR (TEVIMBRA) by BEIGENE, and NIPOCALIMAB-AAHU (IMAAVY) by JANSSEN BIOTECH. All three are designated as 'FALLBACK' approvals and rated bullish (5/10 strength, 5/10 materiality), but the total lack of commercial detail (peak sales, exclusivity, pricing power) renders their immediate investment signal weak. The highest-conviction signal is BEIGENE’s TEVIMBRA label expansion, as it extends the anti-PD-1’s reach into potentially larger oncology indications, reinforcing BEIGENE’s commercial execution in global immuno-oncology. However, the absence of specific indication data, exclusivity periods, or competitor responses limits actionable conclusions.

3 total filings

Federal Construction & Infrastructure Contracts — August 28, 2026

This digest covers a single, high-value civilian infrastructure contract totaling $374.9 million awarded to Hensel Phelps Construction Co. by the General Services Administration for the design and construction of the Raul Hector Castro Land Port of Entry in Arizona. The contract is entirely civilian (0% defense-related) and reflects steady federal investment in border infrastructure under full and open competition. The highest-conviction signal is neutral, given the firm-fixed-price structure over a nearly six-year performance period, which introduces material execution and margin risk. Key watch items include construction material cost trends in the Arizona border region and GSA outlay data to gauge revenue recognition pace.

Defense Manufacturing Contracts — August 28, 2026

A single $99.8M cost-plus-fixed-fee contract from NASA to Lockheed Martin Corp for Mars Ascent Vehicle R&D services dominates this digest, representing 100% of the total obligation and a 0/1 defense-to-civilian split. The contract, awarded under full and open competition, underscores Lockheed's entrenched competitive moat in deep space exploration hardware, with $96.4M already outlayed signaling strong execution progress. The highest-conviction signal is the low-risk cost-plus pricing structure, which ensures stable margins and predictable revenue of ~$36.6M annually through September 2025. Key risks include potential budget cuts to NASA's Mars Sample Return mission and the exercise of $274.4M in options, which would materially increase Lockheed's exposure to this program.

DHS Homeland Security Contracts — August 28, 2026

This digest covers two Department of Homeland Security contracts totaling $782.1 million, both civilian (non-defense) awards, with an average signal strength of 5.5/10. The dominant theme is DHS investment in IT services and aviation support, led by a $580.4 million IBM delivery order for FEMA's EADIS software development, though its negative outlay raises revenue realization concerns. The highest-conviction signal is a $201.7 million sole-source award to PAE Aviation (Amentum) for CBP aviation maintenance, indicating a strong incumbent position in border security logistics. A key risk is the IBM contract's negative outlay, suggesting potential inactivity or termination, which could mislead top-line revenue expectations for investors.

VA Healthcare & Services Contracts — August 28, 2026

This digest covers a single, large civilian contract from the Department of Veterans Affairs (VA) totaling $159.2 million, with no defense-related exposure. The award to OptumRx Administrative Services, LLC, a subsidiary of UnitedHealth Group, is for a four-month pharmacy benefit management (PBM) delivery order under a firm-fixed-price structure, providing high revenue visibility and low execution risk for the period. The highest-conviction signal is the bullish near-term cash flow for UnitedHealth Group, though the short performance window and lack of follow-on orders create a concentration risk. Key watch items include the potential for additional task orders under the same vehicle and the upcoming re-compete for VA PBM services.